Mar 21, 2019 5:05pm EDT IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs
Mar 18, 2019 7:05am EDT IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
Mar 11, 2019 8:41am EDT IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares
Mar 08, 2019 7:05am EST IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019
Mar 07, 2019 7:05am EST IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
Feb 28, 2019 4:51pm EST IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Jan 29, 2019 7:05am EST IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
